PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23198452-7 2012 Tigecycline and colistin maintained excellent activity against most ESBL and carbapenem resistant bacteria relevant to the treatment by these agents. Tigecycline 0-11 EsbL Escherichia coli 68-72 23114764-0 2013 Tigecycline displays in vivo bactericidal activity against extended-spectrum-beta-lactamase-producing Enterobacteriaceae after 72-hour exposure period. Tigecycline 0-11 EsbL Escherichia coli 59-91 23114764-1 2013 Progressively enhanced activity of a humanized tigecycline (TGC) regimen was noted over 3 days against an extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli isolate and an ESBL-producing Klebsiella pneumoniae isolate. Tigecycline 47-58 EsbL Escherichia coli 106-138 23114764-1 2013 Progressively enhanced activity of a humanized tigecycline (TGC) regimen was noted over 3 days against an extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli isolate and an ESBL-producing Klebsiella pneumoniae isolate. Tigecycline 60-63 EsbL Escherichia coli 106-138 22155819-5 2012 The MIC(90) values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 mug/ml, respectively. Tigecycline 22-33 EsbL Escherichia coli 53-57 23214282-15 2012 The effectiveness of tigecycline against ESBL-producing E. coli strains was similar to that of imipenem and meropenem. Tigecycline 21-32 EsbL Escherichia coli 41-45 22155819-5 2012 The MIC(90) values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 mug/ml, respectively. Tigecycline 22-33 EsbL Escherichia coli 77-81 22155819-9 2012 For routine susceptibility testing of ESBL-producing K. pneumoniae and A. baumannii against tigecycline, the broth microdilution method should be used because of the poor correlation of results between these two methods. Tigecycline 92-103 EsbL Escherichia coli 38-42 22203598-4 2012 Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producing E. coli (MIC(90), 0.5 mug/ml) and 96.32% for ESBL-producing K. pneumoniae (MIC(90), 2 mug/ml) when interpreted by FDA criteria but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. Tigecycline 38-49 EsbL Escherichia coli 87-91 22203598-4 2012 Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producing E. coli (MIC(90), 0.5 mug/ml) and 96.32% for ESBL-producing K. pneumoniae (MIC(90), 2 mug/ml) when interpreted by FDA criteria but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. Tigecycline 38-49 EsbL Escherichia coli 147-151 22832033-8 2012 Antimicrobial susceptibility testing of selected, molecularly characterized ESBL producers revealed susceptibility to tigecycline among 97.9% (191/195) of the E. coli and 78.8% (26/33) of the K. pneumoniae isolates. Tigecycline 118-129 EsbL Escherichia coli 76-80 18676620-5 2008 Tigecycline was active against more than 99% of 1936 Escherichia coli isolates characterized by any of the above resistance patterns (including 1636 ESBL-producing isolates) using the US Food and Drug Administration (FDA) breakpoint of susceptibility (MIC < or = 2 mg/L). Tigecycline 0-11 EsbL Escherichia coli 149-153 19015360-2 2009 This study was designed to identify, at the sequence level, the genes responsible for the extended-spectrum-beta-lactamase (ESBL) phenotypes of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during the global tigecycline phase 3 clinical trials. Tigecycline 244-255 EsbL Escherichia coli 90-122 22196060-9 2011 Of the 22 isolates of E. coli with extended-spectrum beta-lactamase (ESBL), the most susceptible antimicrobial agent were colistin (20/22, 91%), ertapenem (21/22, 96%), meropenem and tigecycline (22/22, 100%). Tigecycline 183-194 EsbL Escherichia coli 35-67 20818104-9 2010 In vitro, all ESBL producers were sensitive to tigecycline. Tigecycline 47-58 EsbL Escherichia coli 14-18 20818104-12 2010 Tigecycline is active against all the ESBL or multidrug resistant (MDR) E. coli and Klebsiella spp. Tigecycline 0-11 EsbL Escherichia coli 38-42 19364850-1 2009 Tigecycline is a glycylcycline with activity against Enterobacteriaceae, including multidrug-resistant isolates of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamase (ESBL) and carbapenemases. Tigecycline 0-11 EsbL Escherichia coli 168-200 19364850-1 2009 Tigecycline is a glycylcycline with activity against Enterobacteriaceae, including multidrug-resistant isolates of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamase (ESBL) and carbapenemases. Tigecycline 0-11 EsbL Escherichia coli 202-206 18802728-3 2009 The aim of this study was to assess the in vitro activity of tigecycline against ESBL-producing Escherichia coli, ESBL-producing Klebsiella spp., and multidrug-resistant Enterobacter spp. Tigecycline 61-72 EsbL Escherichia coli 81-85 18802728-3 2009 The aim of this study was to assess the in vitro activity of tigecycline against ESBL-producing Escherichia coli, ESBL-producing Klebsiella spp., and multidrug-resistant Enterobacter spp. Tigecycline 61-72 EsbL Escherichia coli 114-118 19013351-4 2008 Tigecycline had excellent in-vitro activity against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC(90) 0.5 microg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC(90) 2 microg/mL and a 98.5% susceptibility rate. Tigecycline 0-11 EsbL Escherichia coli 52-84 19013351-4 2008 Tigecycline had excellent in-vitro activity against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC(90) 0.5 microg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC(90) 2 microg/mL and a 98.5% susceptibility rate. Tigecycline 0-11 EsbL Escherichia coli 86-90 19013351-4 2008 Tigecycline had excellent in-vitro activity against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC(90) 0.5 microg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC(90) 2 microg/mL and a 98.5% susceptibility rate. Tigecycline 0-11 EsbL Escherichia coli 206-210 18676620-11 2008 In clinical studies, 69.7% of the 33 reported patients treated with tigecycline achieved resolution of an infection caused by a carbapenem-resistant or ESBL-producing or MDR Enterobacteriaceae. Tigecycline 68-79 EsbL Escherichia coli 152-156 18676620-12 2008 CONCLUSIONS: Tigecycline is microbiologically active against almost all of the ESBL or MDR E. coli isolates and the great majority of ESBL or MDR Klebsiella spp. Tigecycline 13-24 EsbL Escherichia coli 79-83 18676620-12 2008 CONCLUSIONS: Tigecycline is microbiologically active against almost all of the ESBL or MDR E. coli isolates and the great majority of ESBL or MDR Klebsiella spp. Tigecycline 13-24 EsbL Escherichia coli 134-138 18154548-2 2008 The activity and potential use of two old antimicrobials, nitrofurantoin and fosfomycin, and the new compound tigecycline for treatment of infections due to ESBL-producing Enterobacteriaceae, with special emphasis on E. coli, are reviewed. Tigecycline 110-121 EsbL Escherichia coli 157-161 18154548-12 2008 Finally, for treatment of systemic infections in the hospital setting, tigecycline could be an option that would reduce selection for ESBL-producing organisms. Tigecycline 71-82 EsbL Escherichia coli 134-138 34022417-9 2021 Susceptibility of extended-spectrum beta-lactamase (ESBL)-negative Escherichia coli to ceftaroline ranged from 67.0% in Asia/SP to 91.0% in Africa/ME; susceptibility to amikacin, meropenem and tigecycline was >=96.7% in all regions. Tigecycline 193-204 EsbL Escherichia coli 18-50 31408445-11 2019 Moreover, three ESBL-producing K. pneumoniae ST11 strains which were resistant to carbapenems carried the blaNDM-1 and blaKPC-2, two of which also bearing blaOXA-48 were resistant to all antibiotics (including Tigecycline). Tigecycline 210-221 EsbL Escherichia coli 16-20 32040455-10 2019 were ESBL producers, susceptible to tigecycline. Tigecycline 36-47 EsbL Escherichia coli 5-9 31505647-5 2019 RESULTS: The annual proportion of isolates of E. coli that were ESBL producing increased from 3.4% in 2007 to 11.1% in 2016 (P < 0.0001); >95% of ESBL-producing E. coli were susceptible to amikacin, colistin, ertapenem, meropenem and tigecycline. Tigecycline 240-251 EsbL Escherichia coli 64-68 27256586-5 2016 Tigecycline resistance has been reported in some studies to be elevated among extended-spectrum beta-lactamase (ESBL)-producing, MDR, extensively drug-resistant and CR isolates. Tigecycline 0-11 EsbL Escherichia coli 78-110 26513341-7 2016 Apart from cephalosporins, ESBL-producing strains were also less likely to be susceptible to other antibiotics, such as quinolones, gentamicin, netilmicin, and cotrimoxazole, more than 90% of which were still susceptible to amikacin, carbapenems, colistin, and tigecycline. Tigecycline 261-272 EsbL Escherichia coli 27-31 24529941-7 2014 Susceptibility of ESBL screen-positive E. coli and K. pneumoniae was 100.0/97.9% for tigecycline and 99.2/56.1% for meropenem, respectively. Tigecycline 85-96 EsbL Escherichia coli 18-22 24421836-2 2013 Although limited in their indications, fosfomycin and tigecycline are potential agents to treat infections due to ESBL-producing organisms. Tigecycline 54-65 EsbL Escherichia coli 114-118 24421836-8 2013 CONCLUSION: Although resistance to these antibiotics has previously been reported, the present study confirmed that isolates of ESBL-producing E coli from the Interior Health Region of British Columbia remain highly susceptible to both tigecycline and fosfomycin. Tigecycline 236-247 EsbL Escherichia coli 128-132